Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neuromyelitis Optica 1Myelitis, Transverse 1Myelitis 1

Interventions

Cyclophosphamide 909Carboplatin 786pembrolizumab 743Paclitaxel 742Cisplatin 708Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 336Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Has results × 4-Aminopyridine × Clear all
NCT02166346 2018-04-17

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Johns Hopkins University

Phase 2 Completed
24 enrolled 10 charts

Myelitis, Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡